Potent Melanin Production Enhancement of Human Tyrosinase Gene by Tat and an Entrapment in Elastic Cationic Niosomes: Potential Application in Vitiligo Gene Therapy

Potent melanin production enhancement of human tyrosinase plasmid (pAH7/Tyr, P) in mouse melanoma cells (B16F10) by Tat peptide (T) and an entrapment in elastic cationic niosomes (E) was described. The E composed of Tween 61/cholesterol/dodecyl dimethyl ammonium bromide at 1:1:0.5 molar ratio was prepared by freeze‐dried emptying liposomes method. PE at P/E ratio of 1:160 w/w and TPE at T/P/E ratio of 0.125:1:160, 0.25:1:160, and 0.5:1:160 w/w/w were prepared. The final concentration of the plasmid in the study was 4 ng/μL. By sulforhodamine B assay, PE and TPE complexes showed slight or no cytotoxic effect. The cells transfected with TPE (0.5:1:160) exhibited the highest enhancement of tyrosinase enzyme activity of 11.82‐, 7.67‐, 5.07‐, and 6.29‐folds of control, P, PE, and TP (0.5:1) and melanin production of 13.03‐, 8.46‐, 5.36‐, and 6.58‐folds of control, P, PE, and TP (0.5:1), respectively. The elastic cationic niosomes demonstrated an increase in thermal stability of P at 4 ± 2, 25 ± 2, and 45 ± 2 °C. The vesicular size and the zeta potential values of PE and TPE complexes were slightly increased but still in the range of stable dispersion (out of ±30 mV). These results indicated the high potential application of the TPE complexes for further investigation for vitiligo gene therapy.

[1]  N. Picci,et al.  A new approach for the evaluation of niosomes as effective transdermal drug delivery systems. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  G. Kibria,et al.  Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[3]  S. Bracke,et al.  Lipid-mediated gene delivery to the skin. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  D. Mishra,et al.  Niosomes: a controlled and novel drug delivery system. , 2011, Biological & pharmaceutical bulletin.

[5]  J. Manosroi,et al.  Cellular uptake enhancement of Tat-GFP fusion protein loaded in elastic niosomes. , 2011, Journal of biomedical nanotechnology.

[6]  A. Manosroi,et al.  Chemical stability and cytotoxicity of human insulin loaded in cationic DPPC/CTA/DDAB liposomes. , 2011, Journal of biomedical nanotechnology.

[7]  J. Manosroi,et al.  Enhancement of transdermal absorption, gene expression and stability of tyrosinase plasmid (pMEL34)-loaded elastic cationic niosomes: potential application in vitiligo treatment. , 2010, Journal of pharmaceutical sciences.

[8]  J. Manosroi,et al.  Anti-inflammatory activity of gel containing novel elastic niosomes entrapped with diclofenac diethylammonium. , 2008, International journal of pharmaceutics.

[9]  Yongzhong Wang,et al.  Polycation nanostructured lipid carrier, a novel nonviral vector constructed with triolein for efficient gene delivery. , 2008, Biochemical and biophysical research communications.

[10]  Jian-Qing Gao,et al.  Liposomes modified with polycation used for gene delivery: preparation, characterization and transfection in vitro. , 2007, International journal of pharmaceutics.

[11]  Kevin G. Rice,et al.  Peptide-guided gene delivery , 2007, The AAPS Journal.

[12]  Shubiao Zhang,et al.  Toxicity of cationic lipids and cationic polymers in gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[13]  H. Maibach,et al.  Elastic vesicles as topical/transdermal drug delivery systems , 2005, International journal of cosmetic science.

[14]  T. Rabbitts,et al.  Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. , 2004, The New England journal of medicine.

[15]  A. Pardakhty,et al.  Development and Physical Characterization of Sorbitan Monoester Niosomes for Insulin Oral Delivery , 2003, Drug delivery.

[16]  E. Smiley,et al.  Low molecular weight disulfide cross-linking peptides as nonviral gene delivery carriers. , 2000, Bioconjugate chemistry.

[17]  J. Bonadio,et al.  Stability of peptide-condensed plasmid DNA formulations. , 1998, Journal of pharmaceutical sciences.

[18]  M. A. Everett,et al.  Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes. , 1993, The Journal of investigative dermatology.

[19]  L. Ingram Mechanism of lysis of Escherichia coli by ethanol and other chaotropic agents , 1981, Journal of bacteriology.

[20]  J. Bouwstra,et al.  Structure of the skin barrier and its modulation by vesicular formulations. , 2003, Progress in lipid research.

[21]  Youngsoo Kim,et al.  Oxyresveratrol and Hydroxystilbene Compounds INHIBITORY EFFECT ON TYROSINASE AND MECHANISM OF ACTION* , 2002 .

[22]  W. Mark Saltzman,et al.  Synthetic DNA delivery systems , 2000, Nature Biotechnology.

[23]  Huang,et al.  Adenovirus technology for gene manipulation and functional studies. , 2000, Drug discovery today.

[24]  M Vapalahti,et al.  [Human gene therapy]. , 1996, Duodecim; laaketieteellinen aikakauskirja.